NO20075752L - Kimeriske proteiner, deres fremstilling og farmasoytiske sammensetninger som inneholder dem - Google Patents

Kimeriske proteiner, deres fremstilling og farmasoytiske sammensetninger som inneholder dem

Info

Publication number
NO20075752L
NO20075752L NO20075752A NO20075752A NO20075752L NO 20075752 L NO20075752 L NO 20075752L NO 20075752 A NO20075752 A NO 20075752A NO 20075752 A NO20075752 A NO 20075752A NO 20075752 L NO20075752 L NO 20075752L
Authority
NO
Norway
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
chimeric proteins
chimeric protein
Prior art date
Application number
NO20075752A
Other languages
English (en)
Norwegian (no)
Inventor
David Wallach
Elena Appel
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20075752L publication Critical patent/NO20075752L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
NO20075752A 2005-04-11 2007-11-09 Kimeriske proteiner, deres fremstilling og farmasoytiske sammensetninger som inneholder dem NO20075752L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL16795905 2005-04-11
PCT/IL2006/000456 WO2006109303A2 (fr) 2005-04-11 2006-04-10 Proteines chimeres et leur preparation, et compositions pharmaceutiques contenant lesdites proteines

Publications (1)

Publication Number Publication Date
NO20075752L true NO20075752L (no) 2008-01-11

Family

ID=36954510

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075752A NO20075752L (no) 2005-04-11 2007-11-09 Kimeriske proteiner, deres fremstilling og farmasoytiske sammensetninger som inneholder dem

Country Status (9)

Country Link
US (1) US8092806B2 (fr)
EP (1) EP1871880B8 (fr)
JP (1) JP5122438B2 (fr)
AU (1) AU2006233929B2 (fr)
CA (1) CA2603779C (fr)
ES (1) ES2389527T3 (fr)
IL (1) IL186258A0 (fr)
NO (1) NO20075752L (fr)
WO (1) WO2006109303A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2642516T3 (es) * 2007-09-04 2017-11-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Supresiones en el dominio II de la exotoxina A de Pseudomonas que reducen la toxicidad no específica
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
WO2012054693A1 (fr) * 2010-10-22 2012-04-26 Trudeau Institute Utilisations du peptide yope de yersinia, gène, et sous-parties de celui-ci en tant que composant vaccinal contre la peste et dosage de lymphocytes t specifiques de yersinia pestis
WO2013041247A1 (fr) * 2011-09-23 2013-03-28 Westfällsche Wilhelms-Universitaet Muenster Protéine m externe de yersinia (yopm) dans le traitement du psoriasis induit par imiquimod
EP2758068A1 (fr) * 2011-09-23 2014-07-30 Westfälische Wilhelms-Universität Münster Protéine m externe de yersinia (yopm) dans le traitement du psoriasis
AU2016227322A1 (en) * 2015-03-03 2017-09-21 Kahr Medical Ltd Dual signaling protein (DSP) fusion proteins, and methods of using thereof for treating diseases
CN105203766B (zh) * 2015-09-29 2017-01-11 河南省科学院生物研究所有限责任公司 一种致病性小肠结肠炎耶尔森氏菌测试条制备方法
EP4316586A3 (fr) 2018-03-08 2024-05-08 Applied Molecular Transport Inc. Constructions d'administration dérivées de toxines pour administration orale
BR112021009001A8 (pt) 2018-11-07 2021-10-26 Applied Molecular Transport Inc Veículos derivados de cholix para administração oral de carga útil heteróloga

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702191D0 (sv) * 1997-06-09 1997-06-09 Sven Pettersson Coposition and methods for the treatment of inflammatory dideases
WO1999052563A1 (fr) * 1998-04-16 1999-10-21 The Regents Of The University Of California Procede de ciblage de proteines produites par le yersinia dans le cytosol de cellules eukariotes
GB0112687D0 (en) * 2001-05-24 2001-07-18 Microbiological Res Authority Pharmaceutical use of secreted bacterial effector proteins

Also Published As

Publication number Publication date
WO2006109303A3 (fr) 2006-12-07
CA2603779C (fr) 2015-05-19
EP1871880B1 (fr) 2012-08-08
EP1871880B8 (fr) 2012-09-12
IL186258A0 (en) 2008-01-20
JP5122438B2 (ja) 2013-01-16
US8092806B2 (en) 2012-01-10
CA2603779A1 (fr) 2006-10-19
ES2389527T3 (es) 2012-10-29
AU2006233929A1 (en) 2006-10-19
EP1871880A2 (fr) 2008-01-02
US20080287356A1 (en) 2008-11-20
JP2008535514A (ja) 2008-09-04
WO2006109303A2 (fr) 2006-10-19
AU2006233929B2 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
NO20075752L (no) Kimeriske proteiner, deres fremstilling og farmasoytiske sammensetninger som inneholder dem
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MY151036A (en) Synthesis of (r)-n-methylnaltrexone
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
CY1118065T1 (el) Καινοτομες αμινογλυκοσιδες και χρησεις αυτων στη θεραπεια γενετικων διαταραχων
NO20044618L (no) Dedifferensierte, programmerbare stamceller av monocyttisk opprinnelse og deres fremstilling og anvendelse
NO20064584L (no) Tetrahydropyridoindolderivater
EA200870599A1 (ru) Стабильные препараты лаквинимода
EA201000399A1 (ru) Композиции и способы использования проостровковых пептидов и их аналогов
BRPI0610108B8 (pt) compostos promotores de apoptose e composição que compreende os ditos compostos
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NO20090628L (no) Pyridizinon derivativater
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
MX2020006822A (es) Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa.
NO20090305L (no) Cyklosporin formuleringer
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
SE0301653D0 (sv) Novel compounds
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
IL171914A0 (en) Variants of il-18bp, their preparation and pharmaceutical compositions containing them
NO20050932L (no) 1-pyridin-4-yl-ureaderivater
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application